Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutationsSatoshi Oizumi, Toshihiro Nukiwa, Akira Inoue et al.|ESMO Open|2018Cited by 43
Randomized phase II study of concurrent gefitinib and chemotherapy versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer (NSCLC) with sensitive <i>EGFR</i> mutations: NEJ005/TCOG0902.Satoshi Oizumi, Shunichi Sugawara, Koichi Minato et al.|Journal of Clinical Oncology|2014Cited by 6
Updated survival outcomes of NEJ005/TCOG0902, a randomized phase II study of concurrent (C) versus sequential alternating (S) gefitinib and chemotherapy in previously untreated non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor (<i>EGFR</i>) mutations.Satoshi Oizumi, Shunichi Sugawara, Koichi Minato et al.|Journal of Clinical Oncology|2017Cited by 4